ES2383799T3 - Procedimiento para la preparación del estereoisómero de glicopirronio con configuración R,R (o S,S) - Google Patents
Procedimiento para la preparación del estereoisómero de glicopirronio con configuración R,R (o S,S) Download PDFInfo
- Publication number
- ES2383799T3 ES2383799T3 ES03782435T ES03782435T ES2383799T3 ES 2383799 T3 ES2383799 T3 ES 2383799T3 ES 03782435 T ES03782435 T ES 03782435T ES 03782435 T ES03782435 T ES 03782435T ES 2383799 T3 ES2383799 T3 ES 2383799T3
- Authority
- ES
- Spain
- Prior art keywords
- diastereoisomers
- formula
- isomer
- stereoisomer
- quaternization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 82
- 239000002904 solvent Substances 0.000 claims abstract description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 45
- 238000005956 quaternization reaction Methods 0.000 claims abstract description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000002244 precipitate Substances 0.000 claims abstract description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960002462 glycopyrronium bromide Drugs 0.000 claims abstract description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 21
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002425 crystallisation Methods 0.000 claims abstract description 20
- 230000008025 crystallization Effects 0.000 claims abstract description 20
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims abstract description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000001298 alcohols Chemical class 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 239000011877 solvent mixture Substances 0.000 claims abstract description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000004090 dissolution Methods 0.000 claims abstract description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 5
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000001953 recrystallisation Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000000926 separation method Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 14
- 150000003839 salts Chemical group 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims 1
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-Butyl ethyl ether Natural products CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 claims 1
- 238000005809 transesterification reaction Methods 0.000 description 17
- 125000001544 thienyl group Chemical group 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 7
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 7
- -1 phenyl compound Chemical class 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 150000001414 amino alcohols Chemical class 0.000 description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940102396 methyl bromide Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 2
- FLVFPAIGVBQGET-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@H](O)C1 FLVFPAIGVBQGET-YFKPBYRVSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940015042 glycopyrrolate Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- FGMUSNHTKNGVQD-UHFFFAOYSA-N methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC)C1CCCC1 FGMUSNHTKNGVQD-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OVGMKPGXRHJNKJ-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1N(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 OVGMKPGXRHJNKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- CYOJLERNTVFORQ-UHFFFAOYSA-N methyl 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate Chemical compound C=1C=CSC=1C(O)(C(=O)OC)C1CCCC1 CYOJLERNTVFORQ-UHFFFAOYSA-N 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT18962002 | 2002-12-18 | ||
| AT0189602A AT412088B (de) | 2002-12-18 | 2002-12-18 | Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere |
| PCT/EP2003/014432 WO2004054971A1 (de) | 2002-12-18 | 2003-12-18 | Verfaren zur herstellung des r,r (oder s,s) konfugurierten glycopyrronium-stereoisomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2383799T3 true ES2383799T3 (es) | 2012-06-26 |
Family
ID=31192804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03782435T Expired - Lifetime ES2383799T3 (es) | 2002-12-18 | 2003-12-18 | Procedimiento para la preparación del estereoisómero de glicopirronio con configuración R,R (o S,S) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7569598B2 (enExample) |
| EP (1) | EP1572641B1 (enExample) |
| JP (1) | JP2007524565A (enExample) |
| CN (1) | CN100349867C (enExample) |
| AT (2) | AT412088B (enExample) |
| AU (1) | AU2003290075B2 (enExample) |
| CA (1) | CA2510280C (enExample) |
| DK (1) | DK1572641T3 (enExample) |
| ES (1) | ES2383799T3 (enExample) |
| NO (1) | NO330851B1 (enExample) |
| NZ (1) | NZ541098A (enExample) |
| PL (1) | PL214802B1 (enExample) |
| PT (1) | PT1572641E (enExample) |
| RU (1) | RU2337096C2 (enExample) |
| WO (1) | WO2004054971A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504463D0 (en) | 2005-03-03 | 2005-04-13 | Arakis Ltd | Method of crystallisation and purification |
| KR101290893B1 (ko) | 2009-04-09 | 2013-07-29 | 노파르티스 아게 | 피롤리디늄 염의 제조 방법 |
| WO2011157387A1 (en) * | 2010-06-14 | 2011-12-22 | Chiesi Farmaceutici S.P.A. | Crystal form of glycopyrronium chloride |
| CN103159659A (zh) * | 2011-12-19 | 2013-06-19 | 沈阳药科大学 | 一种毒蕈碱受体拮抗剂格隆溴铵的制备方法 |
| SMT201700269T1 (it) * | 2011-12-22 | 2017-07-18 | Cerbios Pharma Sa | Procedimento in continuo per l'alchilazione di ammine terziarie cicliche |
| CN102627595A (zh) * | 2012-03-09 | 2012-08-08 | 徐奎 | 一种制备格隆溴铵的方法 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| ES2981043T3 (es) | 2013-02-28 | 2024-10-07 | Journey Medical Corp | Procedimiento para fabricar tosilato de glicopirrolato treo |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN107304178B (zh) * | 2016-04-21 | 2020-03-27 | 辽宁药联制药有限公司 | 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法 |
| CN107345945B (zh) * | 2016-05-05 | 2019-12-17 | 辽宁药联制药有限公司 | 一种拆分格隆溴铵对映体及杂质检查的高效液相色谱方法 |
| CN113234003B (zh) * | 2021-04-23 | 2024-02-02 | 广东嘉博制药有限公司 | 一种格隆溴铵及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2195121T3 (es) * | 1996-11-11 | 2003-12-01 | Christian R Noe | Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento. |
-
2002
- 2002-12-18 AT AT0189602A patent/AT412088B/de not_active IP Right Cessation
-
2003
- 2003-12-18 RU RU2005122497/04A patent/RU2337096C2/ru active
- 2003-12-18 US US10/540,187 patent/US7569598B2/en not_active Expired - Lifetime
- 2003-12-18 AT AT03782435T patent/ATE548348T1/de active
- 2003-12-18 PL PL377441A patent/PL214802B1/pl unknown
- 2003-12-18 PT PT03782435T patent/PT1572641E/pt unknown
- 2003-12-18 DK DK03782435.6T patent/DK1572641T3/da active
- 2003-12-18 JP JP2004560470A patent/JP2007524565A/ja active Pending
- 2003-12-18 NZ NZ541098A patent/NZ541098A/en not_active IP Right Cessation
- 2003-12-18 CA CA2510280A patent/CA2510280C/en not_active Expired - Fee Related
- 2003-12-18 AU AU2003290075A patent/AU2003290075B2/en not_active Ceased
- 2003-12-18 ES ES03782435T patent/ES2383799T3/es not_active Expired - Lifetime
- 2003-12-18 WO PCT/EP2003/014432 patent/WO2004054971A1/de not_active Ceased
- 2003-12-18 EP EP03782435A patent/EP1572641B1/de not_active Expired - Lifetime
- 2003-12-18 CN CNB2003801098187A patent/CN100349867C/zh not_active Expired - Fee Related
-
2005
- 2005-07-15 NO NO20053473A patent/NO330851B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATA18962002A (de) | 2004-02-15 |
| US7569598B2 (en) | 2009-08-04 |
| WO2004054971A1 (de) | 2004-07-01 |
| CN1751022A (zh) | 2006-03-22 |
| AU2003290075A1 (en) | 2004-07-09 |
| PT1572641E (pt) | 2012-06-15 |
| PL377441A1 (pl) | 2006-02-06 |
| PL214802B1 (pl) | 2013-09-30 |
| RU2337096C2 (ru) | 2008-10-27 |
| NO20053473D0 (no) | 2005-07-15 |
| EP1572641B1 (de) | 2012-03-07 |
| CN100349867C (zh) | 2007-11-21 |
| CA2510280A1 (en) | 2004-07-01 |
| US20060167275A1 (en) | 2006-07-27 |
| DK1572641T3 (da) | 2012-07-02 |
| AU2003290075B2 (en) | 2009-01-29 |
| CA2510280C (en) | 2011-09-27 |
| AT412088B (de) | 2004-09-27 |
| NO330851B1 (no) | 2011-08-01 |
| NO20053473L (no) | 2005-09-19 |
| NZ541098A (en) | 2008-08-29 |
| EP1572641A1 (de) | 2005-09-14 |
| ATE548348T1 (de) | 2012-03-15 |
| RU2005122497A (ru) | 2006-01-20 |
| JP2007524565A (ja) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2407135T3 (es) | Uso de (3S,2'R)-glicopirronio como medicamento | |
| ES2383799T3 (es) | Procedimiento para la preparación del estereoisómero de glicopirronio con configuración R,R (o S,S) | |
| CN107949558B (zh) | 毒蕈碱激动剂 | |
| ES2209158T3 (es) | Resolucion de aminas. | |
| JP5503546B2 (ja) | ４，５−ジメトキシ−１−（メチルアミノメチル）−ベンゾシクロブタンの分離 | |
| US11584715B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| WO2013114173A1 (en) | A novel process for the preparation of sitagliptin | |
| JP2007524565A5 (enExample) | ||
| JP7126522B2 (ja) | （＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用 | |
| CN112739686B (zh) | 用于制备(-)-西苯唑啉琥珀酸盐的新方法 | |
| Tayama et al. | Resolution of nitrogen-centered chiral tetraalkylammonium salts: application to [1, 2] Stevens rearrangements with N-to-C chirality transmission | |
| JPH01186866A (ja) | 分割化アミノピロリジン神経防護剤 | |
| Ha et al. | A Novel synthetic method for Bepotastine, a histamine H1 receptor antagonist | |
| JP7669388B2 (ja) | ４，５－ジヒドロ－１ｈ－ピラゾール及び中間体を製造する方法 | |
| CN114341362B (zh) | 一种(r)-1,2,3,4-四氢异喹啉-1-羧酸及其衍生物和左旋吡喹酮的制备方法 | |
| ES2284078T3 (es) | Procedimiento para la redisolucion de nefopam. | |
| US11091436B2 (en) | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | |
| ES2324136B1 (es) | Nuevo procedimiento de sintesis y purificacion de (s)-zopiclone cristalino anhidro. | |
| FR2527210A1 (fr) | Enantiomeres d'hexahydro-2,3,3a,4,5,6 1h-indolo(3,2,1-de) (naphtyridine-1,5), leur procede de separation et leur application en therapeutique | |
| JP3706160B2 (ja) | 光学活性なジアザビシクロヘプテン誘導体の製造法 | |
| FR2610322A1 (fr) | Nouveaux derives de la pilocarpine, leur preparation et leur utilisation comme medicaments | |
| US20090227623A1 (en) | Deuterium-enriched palosetron | |
| ITMI20071657A1 (it) | Procedimento per la sintesi del nebivololo | |
| HK1128458B (en) | Resolution of 4, 5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane |